3SBio (83B) Stock Overview
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
83B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.54 |
| 52 Week High | HK$3.88 |
| 52 Week Low | HK$0.80 |
| Beta | 0.69 |
| 1 Month Change | -5.93% |
| 3 Month Change | -21.12% |
| 1 Year Change | 211.66% |
| 3 Year Change | 170.21% |
| 5 Year Change | 217.50% |
| Change since IPO | 138.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 83B | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.3% | -2.3% | 1.6% |
| 1Y | 211.7% | 5.9% | 7.9% |
Return vs Industry: 83B exceeded the German Biotechs industry which returned 5% over the past year.
Return vs Market: 83B exceeded the German Market which returned 7.3% over the past year.
Price Volatility
| 83B volatility | |
|---|---|
| 83B Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.9% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 83B has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 83B's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 6,268 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC external medicine for treating hair loss; and SPARIN, an injectable low-molecular-weight heparin calcium.
3SBio Inc. Fundamentals Summary
| 83B fundamental statistics | |
|---|---|
| Market cap | €6.48b |
| Earnings (TTM) | €289.70m |
| Revenue (TTM) | €1.11b |
Is 83B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 83B income statement (TTM) | |
|---|---|
| Revenue | CN¥9.07b |
| Cost of Revenue | CN¥1.33b |
| Gross Profit | CN¥7.75b |
| Other Expenses | CN¥5.39b |
| Earnings | CN¥2.36b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 85.37% |
| Net Profit Margin | 25.99% |
| Debt/Equity Ratio | 9.7% |
How did 83B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/20 13:57 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
3SBio Inc. is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Yu | China International Capital Corporation Limited |
| Zhuhong Chen | China Merchants Securities (HK) Co., Ltd |
| Fangqi Dai | China Merchants Securities (HK) Co., Ltd |